Nektar Therapeutics
American healthcare company
NKTR Nasdaq
ISIN US6402683063 SEC CIK 906709 LEI 5299005I24806IOIYE03
Follow Nektar Therapeutics
Weekly email: filings, results
Revenue, last quarter
$9.4M
−20.4% vs same quarter last year
Net income
−$55.7M
−56.7% vs same quarter last year
EPS, diluted
−$1.63
+12.8% vs same quarter last year
Operating cash flow
−$71.9M
−47.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $55.2M | −$164M |
| FY24 | $98.4M | −$119M |
| FY23 | $90.1M | −$276M |
| FY22 | $92.1M | −$368M |
| FY21 | $101.9M | −$524M |
| FY20 | $152.9M | −$444.4M |
| FY19 | $114.6M | −$440.7M |
| FY18 | $1.2B | $681.3M |
| FY17 | $307.7M | −$96.7M |
| FY16 | $165.4M | −$153.5M |
| FY15 | $230.8M | −$81.2M |
| FY14 | $200.7M | −$53.9M |
| FY13 | $148.9M | −$162M |
| FY12 | $81.2M | −$171.9M |
| FY11 | $71.5M | −$134M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 100% | −253.7% | −296.9% |
| FY24 | 68.8% | −106.9% | −120.9% |
| FY23 | 62.5% | −292.6% | −306.3% |
| FY22 | 76.5% | −408.6% | −399.8% |
| FY21 | 75.6% | −437.8% | −514.2% |
| FY20 | 87.3% | −278% | −290.6% |
| FY19 | 81.4% | −383.9% | −384.5% |
| FY18 | 98% | 57.6% | 57.1% |
| FY17 | 90.1% | −19.4% | −31.4% |
| FY16 | 81.7% | −68.2% | −92.8% |
| FY15 | 85.2% | −12.7% | −35.2% |
| FY14 | 85.8% | −8.2% | −26.9% |
| FY13 | 74.1% | −80.7% | −108.8% |
| FY12 | 62.5% | −173.9% | −211.7% |
| FY11 | 69.4% | −173.4% | −187.4% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$208.7M |
| FY24 | −$177.2M |
| FY23 | −$193.5M |
| FY22 | −$309.7M |
| FY21 | −$427.6M |
| FY20 | −$320.5M |
| FY19 | −$355M |
| FY18 | $704M |
| FY17 | −$90.1M |
| FY16 | −$123.4M |
| FY15 | −$84.3M |
| FY14 | −$152M |
| FY13 | −$42.6M |
| FY12 | −$140.3M |
| FY11 | −$123.5M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $0 |
| FY24 | $3M |
| FY23 | $0 |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Nektar Therapeutics
- Healthcare median
Show the numbers
| Year | Nektar Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −296.9% | −30.6% |
| FY24 | −120.9% | −47% |
| FY23 | −306.3% | −58% |
| FY22 | −399.8% | −80.4% |
| FY21 | −514.2% | −71.8% |
| FY20 | −290.6% | −62.2% |
| FY19 | −384.5% | −46.2% |
| FY18 | 57.1% | −49.6% |
| FY17 | −31.4% | −45.9% |
| FY16 | −92.8% | −36% |
| FY15 | −35.2% | −37.8% |
| FY14 | −26.9% | −35.5% |
| FY13 | −108.8% | −37.1% |
| FY12 | −211.7% | −29.1% |
| FY11 | −187.4% | −27.9% |